JP2020525436A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020525436A5 JP2020525436A5 JP2019570906A JP2019570906A JP2020525436A5 JP 2020525436 A5 JP2020525436 A5 JP 2020525436A5 JP 2019570906 A JP2019570906 A JP 2019570906A JP 2019570906 A JP2019570906 A JP 2019570906A JP 2020525436 A5 JP2020525436 A5 JP 2020525436A5
- Authority
- JP
- Japan
- Prior art keywords
- controlled release
- compound
- dosage form
- gastric resistance
- resistance controlled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023147484A JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
| JP2025101290A JP2025134828A (ja) | 2017-06-21 | 2025-06-17 | 胃耐性制御放出経口剤形 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523204P | 2017-06-21 | 2017-06-21 | |
| US62/523,204 | 2017-06-21 | ||
| PCT/US2018/038853 WO2018237207A1 (en) | 2017-06-21 | 2018-06-21 | GESTRO-RESISTANT ORAL DOSAGE FORMS WITH CONTROLLED RELEASE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023147484A Division JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020525436A JP2020525436A (ja) | 2020-08-27 |
| JP2020525436A5 true JP2020525436A5 (enExample) | 2021-07-29 |
Family
ID=62904624
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570906A Pending JP2020525436A (ja) | 2017-06-21 | 2018-06-21 | 胃耐性制御放出経口剤形 |
| JP2023147484A Pending JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
| JP2025101290A Pending JP2025134828A (ja) | 2017-06-21 | 2025-06-17 | 胃耐性制御放出経口剤形 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023147484A Pending JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
| JP2025101290A Pending JP2025134828A (ja) | 2017-06-21 | 2025-06-17 | 胃耐性制御放出経口剤形 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11464744B2 (enExample) |
| EP (1) | EP3641732A1 (enExample) |
| JP (3) | JP2020525436A (enExample) |
| CN (1) | CN111511353A (enExample) |
| AU (2) | AU2018290287B2 (enExample) |
| BR (1) | BR112019027398A2 (enExample) |
| CA (1) | CA3067031A1 (enExample) |
| CL (1) | CL2019003743A1 (enExample) |
| CO (1) | CO2019014496A2 (enExample) |
| IL (3) | IL319156A (enExample) |
| MX (1) | MX2023002994A (enExample) |
| PE (1) | PE20200732A1 (enExample) |
| UA (1) | UA127349C2 (enExample) |
| WO (1) | WO2018237207A1 (enExample) |
| ZA (1) | ZA202409847B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015355226B2 (en) | 2014-12-02 | 2020-04-02 | Minerva Neurosciences, Inc. | Compositions comprising 2-((1-(2(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
| IL319156A (en) | 2017-06-21 | 2025-04-01 | Minerva Neurosciences Inc | Controlled-release oral dosage forms are resistant to gastric acid. |
| US11083723B2 (en) | 2018-08-21 | 2021-08-10 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| IT201800011125A1 (it) * | 2018-12-14 | 2020-06-14 | Dpl Pharma S P A | Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico |
| US20230255953A1 (en) | 2022-02-14 | 2023-08-17 | Minerva Neurosciences, Inc. | Use of roluperidone in preventing relapse in schizophrenia patients |
| WO2025090588A1 (en) | 2023-10-24 | 2025-05-01 | Minerva Neurosciences, Inc. | Roluperidone for the treatment of lysosomal storage disorders and their symptoms |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3888340T2 (de) | 1988-01-21 | 1994-06-30 | Merrell Dow Pharma | Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit. |
| CA2069318A1 (en) | 1989-10-27 | 1991-04-28 | Engelbert Ciganek | (n-phthalimidoalkyl) piperidines |
| KR100259107B1 (ko) | 1992-04-23 | 2000-07-01 | 슈테펜 엘. 네스비트 | 세로토닌 5ht₂길항제로서의 4-이미도메틸-1-[2'-페닐-2'-옥소에틸]피페리딘, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
| NZ521576A (en) | 2000-02-29 | 2005-06-24 | Mitsubishi Pharma Corp | Novel cyclic amide derivatives |
| JP5049450B2 (ja) | 2000-09-29 | 2012-10-17 | アボツト・ヘルスケア・プロダクツ・ベー・ブイ | イオン強度に依存しない徐放性製薬組成物 |
| US20050095292A1 (en) | 2003-10-29 | 2005-05-05 | Wyeth | Sustained release pharmaceutical compositions |
| MY147202A (en) * | 2003-11-26 | 2012-11-14 | Novartis Ag | Compositions comprising organic compounds |
| TW200616608A (en) | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| EP1891002B1 (en) | 2005-06-06 | 2012-05-30 | Merck Sharp & Dohme Limited | Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia |
| EP1986647A4 (en) | 2006-02-07 | 2009-09-02 | Mitsubishi Tanabe Pharma Corp | BY NEUROGENESIS MEDIATED BY 4-ACYLAMINOPYRIDINE DERIVATIVES |
| CA2569776A1 (en) | 2006-02-17 | 2007-08-17 | Kos Life Sciences, Inc. | Low flush niacin formulation |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| JP2008273954A (ja) | 2007-03-30 | 2008-11-13 | Mitsubishi Tanabe Pharma Corp | うつ病の予防及び／又は治療剤 |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| EP2246331A1 (en) | 2009-04-24 | 2010-11-03 | Westfälische Wilhelms-Universität Münster | NR2B-selective NMDA-receptor antagonists |
| ES2530049T3 (es) | 2009-05-18 | 2015-02-26 | Sigmoid Pharma Limited | Composición que comprende gotas de aceite |
| WO2011158870A1 (ja) | 2010-06-16 | 2011-12-22 | 帝人ファーマ株式会社 | 放出制御型の有核錠剤 |
| RU2746871C2 (ru) | 2010-07-20 | 2021-04-21 | Сиренейк Фармасьютикалз Инк. | Способы применения производных циклического амида для лечения опосредуемых сигма-рецепторами расстройств |
| SI3135286T1 (sl) | 2010-07-20 | 2024-02-29 | Minerva Neurosciences, Inc. | Postopek uporabe derivatov cikličnega amida za zdravljenje shizofrenije in njenih simptomov |
| US8937900B2 (en) | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| US20120040008A1 (en) * | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| EP2468264A1 (en) * | 2010-12-27 | 2012-06-27 | Laboratorios Liconsa, S.A. | Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| EP2685966A1 (en) | 2011-03-17 | 2014-01-22 | Lupin Limited | Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor |
| JP6191883B2 (ja) * | 2011-08-16 | 2017-09-06 | カーディオラ ピーティーワイ リミテッド | 制御放出製剤 |
| RU2015140610A (ru) * | 2013-03-14 | 2017-04-17 | ТЕРАБАЙОМ, ЭлЭлСи | Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств |
| CN104586771B (zh) * | 2013-10-30 | 2018-01-16 | 广州朗圣药业有限公司 | 一种盐酸坦洛新缓释微丸制剂 |
| JP2017514832A (ja) * | 2014-04-30 | 2017-06-08 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ１抑制剤を調製する方法及びその新しい形態 |
| JP6531093B2 (ja) | 2014-05-16 | 2019-06-12 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| WO2015191554A1 (en) | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| AU2015301596B2 (en) * | 2014-08-13 | 2020-04-16 | Cedars-Sinai Medical Center | Anti-methanogenic compositions and uses thereof |
| AU2015355226B2 (en) * | 2014-12-02 | 2020-04-02 | Minerva Neurosciences, Inc. | Compositions comprising 2-((1-(2(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
| US10617650B2 (en) * | 2015-10-16 | 2020-04-14 | Merck Sharp & Dohme Corp. | Process for preparing formulations for gastrointestinal-targeted therapies |
| EP3463356A1 (en) | 2016-05-25 | 2019-04-10 | Minerva Neurosciences, Inc. | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
| IL319156A (en) | 2017-06-21 | 2025-04-01 | Minerva Neurosciences Inc | Controlled-release oral dosage forms are resistant to gastric acid. |
| US11083723B2 (en) | 2018-08-21 | 2021-08-10 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| WO2020264486A1 (en) | 2019-06-28 | 2020-12-30 | Teva Czech Industries S.R.O | Solid state forms of roluperidone and salts thereof |
| US20230255953A1 (en) | 2022-02-14 | 2023-08-17 | Minerva Neurosciences, Inc. | Use of roluperidone in preventing relapse in schizophrenia patients |
-
2018
- 2018-06-21 IL IL319156A patent/IL319156A/en unknown
- 2018-06-21 IL IL271606A patent/IL271606B2/en unknown
- 2018-06-21 US US16/015,151 patent/US11464744B2/en active Active
- 2018-06-21 EP EP18740435.5A patent/EP3641732A1/en active Pending
- 2018-06-21 PE PE2019002573A patent/PE20200732A1/es unknown
- 2018-06-21 AU AU2018290287A patent/AU2018290287B2/en active Active
- 2018-06-21 CA CA3067031A patent/CA3067031A1/en active Pending
- 2018-06-21 JP JP2019570906A patent/JP2020525436A/ja active Pending
- 2018-06-21 UA UAA202000290A patent/UA127349C2/uk unknown
- 2018-06-21 BR BR112019027398-0A patent/BR112019027398A2/pt active Search and Examination
- 2018-06-21 IL IL308650A patent/IL308650B2/en unknown
- 2018-06-21 CN CN201880054407.9A patent/CN111511353A/zh active Pending
- 2018-06-21 WO PCT/US2018/038853 patent/WO2018237207A1/en not_active Ceased
-
2019
- 2019-12-18 MX MX2023002994A patent/MX2023002994A/es unknown
- 2019-12-18 CL CL2019003743A patent/CL2019003743A1/es unknown
- 2019-12-20 CO CONC2019/0014496A patent/CO2019014496A2/es unknown
-
2022
- 2022-06-15 US US17/841,284 patent/US12048768B2/en active Active
-
2023
- 2023-09-12 JP JP2023147484A patent/JP2023175778A/ja active Pending
-
2024
- 2024-06-10 US US18/738,782 patent/US20250009665A1/en active Pending
- 2024-09-13 AU AU2024219717A patent/AU2024219717A1/en active Pending
- 2024-12-19 ZA ZA2024/09847A patent/ZA202409847B/en unknown
-
2025
- 2025-06-17 JP JP2025101290A patent/JP2025134828A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020525436A5 (enExample) | ||
| JP6084161B2 (ja) | ７−［４−（４−ベンゾ［ｂ］チオフェン−４−イル−ピペラジン−１−イル）ブトキシ］−１Ｈ−キノリン−２−オン又はその塩を含む錠剤 | |
| FI117961B (fi) | Nopeasti vaikutuksen aloittava formulaatio | |
| JP2015506377A5 (enExample) | ||
| CN110035757A (zh) | 一种奥拉帕尼口服缓控释药物组合物及其用途 | |
| JP2011513391A (ja) | ミコフェノラートを含有する徐放性医薬組成物およびその方法 | |
| JP2009525343A5 (enExample) | ||
| CN105142618A (zh) | 提供药理及临床效应的莫沙必利每日单次施用缓释制剂 | |
| JP2014501267A (ja) | メサラジン制御放出用の経口用医薬錠剤および前記錠剤を得るための製法 | |
| JP2015510916A5 (enExample) | ||
| JP2013529665A5 (enExample) | ||
| WO2014029953A1 (en) | Hot melt extruded (hme) pharmaceutical composition of cinacalcet | |
| AU2014279743B2 (en) | Modified release formulation | |
| EP2841061A1 (en) | Methods for treating cardiovascular disorder | |
| JP2015509539A5 (enExample) | ||
| CN101431992A (zh) | 包含尼美舒利的新型低剂量药物组合物及其制备和用途 | |
| JP2016530238A5 (enExample) | ||
| JP2010538062A5 (enExample) | ||
| CN110035751A (zh) | 一种维利帕尼缓控释药物组合物及其用途 | |
| EP3326653A1 (en) | Delayed release dosage forms comprising dimethyl fumarate | |
| WO2022138717A1 (ja) | 経口固形製剤 | |
| JP6854162B2 (ja) | 錠剤 | |
| JP6815109B2 (ja) | デュロキセチンまたは薬学的に許容されるその塩を有効成分とする医薬組成物 | |
| CA2854612C (en) | Delivery systems for improving oral bioavailability of fenobam, its hydrates, and salts | |
| WO2017174096A1 (en) | Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof |